Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CMA1 | P23946 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7885318 | 0.81 | TSHR (0.76) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL15478270 | 0.80 | TSHR (0.82) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12892041 | 0.77 | TSHR (0.78) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7892606 | 0.76 | MEN1 (0.74) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL11985477 | 0.76 | TSHR (0.76) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7894969 | 0.76 | TSHR (0.66) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12877772 | 0.74 | TSHR (0.71) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10342551 | 0.73 | TSHR (0.75) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7894987 | 0.72 | GAA (0.82) | TSHRPOLBATMGAAMAPT | |
| SCHEMBL7960258 | 0.71 | CMA1 (1.00) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021092-A1 | STRUCTURE-BASED DESIGN OF A NOVEL CLASS OF DRUGS FOR NEURODEGENERATIVE DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021092-A1 | STRUCTURE-BASED DESIGN OF A NOVEL CLASS OF DRUGS FOR NEURODEGENERATIVE DISEASE | SNCA, MAPT, PSEN2 | TSHR 2821/4885CYP1A2 1143/4885CYP3A4 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.